Ocular Therapeutix Inc (OCUL)

3.64
NASDAQ
Prev Close 3.64
Day Low/High 0.00 / 0.00
52 Wk Low/High 3.46 / 8.28
Exchange NASDAQ
Shares Outstanding 42.84B
Market Cap 155.93M
Div & Yield N.A. (N.A)

Latest News

Ocular Therapeutix™ Reports Election Of Leslie Williams To Board Of Directors

Ocular Therapeutix™ Reports Election Of Leslie Williams To Board Of Directors

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the election of Leslie J.

Ocular Therapeutix™ To Host 2019 Research & Development Day

Ocular Therapeutix™ To Host 2019 Research & Development Day

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will host a Research & Development...

First Week Of May 17th Options Trading For Ocular Therapeutix (OCUL)

First Week Of May 17th Options Trading For Ocular Therapeutix (OCUL)

Investors in Ocular Therapeutix Inc saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OCUL options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

Ocular Therapeutix™ Reports Fourth Quarter And Year End 2018 Financial Results And Business Update

Ocular Therapeutix™ Reports Fourth Quarter And Year End 2018 Financial Results And Business Update

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the fourth quarter...

Ocular Therapeutix™ To Present At The Cowen And Company 39th Annual Health Care Conference

Ocular Therapeutix™ To Present At The Cowen And Company 39th Annual Health Care Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Michael Goldstein, M.

Ocular Therapeutix™ To Report Fourth Quarter And Year End 2018 Financial Results

Ocular Therapeutix™ To Report Fourth Quarter And Year End 2018 Financial Results

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report fourth quarter and...

Ocular Therapeutix™ Prices $37.5 Million Subordinated Convertible Debt Financing

Ocular Therapeutix™ Prices $37.5 Million Subordinated Convertible Debt Financing

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has entered into a note purchase...

Ocular Therapeutix™ Announces Dosing Of First Patient In OTX-TKI (tyrosine Kinase Inhibitor Implant) Phase 1 Clinical Trial For The Treatment Of Wet Age-related Macular Degeneration (AMD)

Ocular Therapeutix™ Announces Dosing Of First Patient In OTX-TKI (tyrosine Kinase Inhibitor Implant) Phase 1 Clinical Trial For The Treatment Of Wet Age-related Macular Degeneration (AMD)

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the dosing of the first patient in a Phase...

OCUL: Insiders Vs. Shorts

OCUL: Insiders Vs. Shorts

The most recent short interest data was recently released for the 01/31/2019 settlement date, and Ocular Therapeutix Inc is one of the most shorted stocks of the Russell 3000, based on 17.05 "days to cover" versus the median component at 4.98. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Ocular Therapeutix™ Submits Supplemental New Drug Application (sNDA) For DEXTENZA® (dexamethasone Ophthalmic Insert) For The Treatment Of Ocular Inflammation Following Ophthalmic Surgery

Ocular Therapeutix™ Submits Supplemental New Drug Application (sNDA) For DEXTENZA® (dexamethasone Ophthalmic Insert) For The Treatment Of Ocular Inflammation Following Ophthalmic Surgery

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the submission of a supplemental New Drug...

Interesting OCUL Call Options For February 15th

Interesting OCUL Call Options For February 15th

Investors in Ocular Therapeutix Inc saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OCUL options chain for the new February 15th contracts and identified the following call contract of particular interest.

Ocular Therapeutix™ Announces Completion Of Debt Refinancing

Ocular Therapeutix™ Announces Completion Of Debt Refinancing

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has closed a refinancing of its...

Ocular Therapeutix™ Added To Nasdaq Biotechnology Index

Ocular Therapeutix™ Added To Nasdaq Biotechnology Index

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has been selected for addition to...

Ocular Therapeutix™ Announces The Hiring Of Chad Brines, Vice President, Sales

Ocular Therapeutix™ Announces The Hiring Of Chad Brines, Vice President, Sales

Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the hiring of Chad Brines as Vice...

Ocular Therapeutix™ Announces FDA Approval Of DEXTENZA® For The Treatment Of Ocular Pain Following Ophthalmic Surgery

Ocular Therapeutix™ Announces FDA Approval Of DEXTENZA® For The Treatment Of Ocular Pain Following Ophthalmic Surgery

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.

Ocular Therapeutix Breaks Above 200-Day Moving Average - Bullish For OCUL

Ocular Therapeutix Breaks Above 200-Day Moving Average - Bullish For OCUL

In trading on Friday, shares of Ocular Therapeutix Inc crossed above their 200 day moving average of $6.30, changing hands as high as $6.88 per share. Ocular Therapeutix Inc shares are currently trading up about 12% on the day.

Ocular Therapeutix™ To Present At The 30th Annual Piper Jaffray Healthcare Conference

Ocular Therapeutix™ To Present At The 30th Annual Piper Jaffray Healthcare Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief...

OCUL: Insiders Vs. Shorts

OCUL: Insiders Vs. Shorts

The most recent short interest data was recently released for the 10/31/2018 settlement date, and Ocular Therapeutix Inc is one of the most shorted stocks of the Russell 3000, based on 9.62 "days to cover" versus the median component at 4.44. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Ocular Therapeutix™ Reports Third Quarter 2018 Financial Results And Business Update

Ocular Therapeutix™ Reports Third Quarter 2018 Financial Results And Business Update

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the third quarter...

Ocular Therapeutix™ To Report Third Quarter 2018 Financial Results

Ocular Therapeutix™ To Report Third Quarter 2018 Financial Results

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third quarter ended...

Relative Strength Alert For Ocular Therapeutix

Relative Strength Alert For Ocular Therapeutix

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ocular Therapeutix™ Receives FDA Warning Letter Related To ReSure® Sealant

Ocular Therapeutix™ Receives FDA Warning Letter Related To ReSure® Sealant

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the receipt of a warning letter from the U.

OCUL Makes Notable Cross Below Critical Moving Average

OCUL Makes Notable Cross Below Critical Moving Average

In trading on Friday, shares of Ocular Therapeutix Inc crossed below their 200 day moving average of $6.21, changing hands as low as $6.13 per share. Ocular Therapeutix Inc shares are currently trading down about 6.1% on the day.

First Week Of OCUL November 16th Options Trading

First Week Of OCUL November 16th Options Trading

Investors in Ocular Therapeutix Inc saw new options become available this week, for the November 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OCUL options chain for the new November 16th contracts and identified one put and one call contract of particular interest.

Ocular Therapeutix™ To Present At The 2018 Cantor Global Healthcare Conference

Ocular Therapeutix™ To Present At The 2018 Cantor Global Healthcare Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief...

Ocular Therapeutix™ To Present At The H.C. Wainwright 20th Annual Global Investment Conference

Ocular Therapeutix™ To Present At The H.C. Wainwright 20th Annual Global Investment Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief...

OCUL: Insiders Vs. Shorts

OCUL: Insiders Vs. Shorts

The most recent short interest data was recently released for the 07/31/2018 settlement date, and Ocular Therapeutix Inc is one of the most shorted stocks of the Russell 3000, based on 13.22 "days to cover" versus the median component at 5.19. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

TheStreet Quant Rating: D- (Sell)